Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEDSVJ)

• Drug Name: Ociperlimab Drug Info
• Synonyms: BGB-A1217

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 3	[1]
Cervical cancer	2C77.0	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DMEDSVJ

Molecule-Related Drug Atlas

Drug(s) Targeting V-set and immunoglobulin domain-containing protein 9 (TIGIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AB154	DMUES7Y	Non-small-cell lung cancer	2C25	Phase 3	[4]
GSK4428859	DMIOIU8	Aggressive cancer	2A00-2F9Z	Phase 2	[5]
Rilvegostomig	DMDWCM2	Non-small-cell lung cancer	2C25	Phase 1/2	[6]
ASP8374	DMA71OL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
SEA-TGT	DM7GUH3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
COM902	DMR6T8L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
M6223	DM6J085	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
V-set and immunoglobulin domain-containing protein 9 (TIGIT)	TTWNL74	TIGIT_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT04746924) A Study of BGB-A1217 With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT04693234) AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of BeiGene.
• [4] Clinical pipeline report, company report or official report of Arcus Biosciences.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [6] ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of Seagen.
• [9] COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26.
• [10] ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health.